MD-Gastroview® (solution of 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium Solution) is an iodinated oral contrast agent with lemon-vanilla-flavor. MD-Gastroview® is water-soluble and suitable for oral or rectal administration.
MD-Gastroview® is indicated for radiographic and CT examination of the esophagus, stomach, proximal small intestine and colon, when a barium sulfate suspension is not feasible or contraindicated.
A usual adult dose for abdominal CT is 240 mL of a solution prepared by diluting 25 mL (9.17 g iodine) to one liter with tap water. Less dilute solutions [up to 77 mL (28.26 g iodine) diluted to one liter with tap water] may be used when indicated. The dose is administered orally about 15 to 30 minutes prior to imaging in order to permit the contrast medium to reach the pelvic loops.

The mammography quality standards act (MQSA) was established in 1994 and commit all mammography facilities in the United States to be accredited by an approved body and undergo annual inspections by state or federal inspectors. The Food and Drug Administration (FDA) is responsible for implementing MQSA and to develop national mammography regulations.

(MPI) The myocardial perfusion scan is the most common nuclear medicine procedure in cardiac imaging and allows assessing the blood-flow patterns to the heart muscles. The comparison of the radiopharmaceutical distribution after stress and at rest provides information on myocardial viability and cardiac perfusion abnormalities. ECG-gated myocardial perfusion imaging allows the assessment of global and regional myocardial function such as wall motion abnormalities.
The diagnostic accuracy of myocardial perfusion scintigraphy (also abbreviated MPS) allows reliable risk stratification and guides the selection of patients for further interventions, such as revascularization. MPI also has particular advantages over alternative techniques in the management of a number of patient subgroups, including women, the elderly, and those with diabetes. The use of this type of cardiac scintigraphy is associated with greater cost effectiveness of treatment, in terms of life-years saved, particularly in these special patient groups.
Myocardial perfusion scintigrams are acquired with a gamma camera. Single photon emission computed tomography (SPECT) is preferred over planar imaging because of the three dimensional nature of the images and their superior contrast resolution.
Common MPI radiopharmaceuticals, approved by the U.S. Food and Drug Administration (FDA) include: Tl-201 and the Tc-99m-labeled radiopharmaceuticals, such as sestamibi, tetrofosmin, and teboroxime for single-photon imaging. Rb-82 is used for positron emission tomography (PET) imaging.

See also Gated Blood Pool Scintigraphy, Myocardial Late Enhancement, Cardiac MRI and Echocardiography.

The basis of pulmonary scintigraphy is the detection of gamma rays emitted from the lung after administration of a radioactive tracer.
See Lung Scintigraphy.

See also Aerosol Ventilation Scintigraphy, Gas Ventilation Scintigraphy, Pulmonary Perfusion Scintigraphy, Computed Tomography Pulmonary Angiography and Lung Imaging.

Reno-30® is a radiopaque contrast agent indicated for retrograde or ascending pyelography. Retrograde pyelography does not include systemic administration of contrast media, so the risk of adverse reactions is extremely rare.